Aided by government funding and big pharma partnerships, South Korea is staking its claim on biosimilars, with Celltrion and Samsung the main contenders.

1. South Korea Comes to the
Fore in Biosimilars Space
Powered by Small World Social
www.biolink.us

2. Powered by Small World Social
Aided by government funding and
big pharma partnerships, South
Korea is staking its claim on
biosimilars, with Celltrion and
Samsung the main contenders.
2Biolink.us

3. Powered by Small World Social
South Korea is pushing to be a leader in the
biopharmaceuticals field, so says a recent
Financial Times report. While that country’s
Celltrion is already a big player in
manufacturing, partnering with Pfizer-owned
Hospira, Samsung’s more recent foray into the
research and development of biosimilars in
particular should be interesting to watch, given
the company continues to take a bite out of
Apple’s market share in the
smartphone/smartwatch space.
3Biolink.us

4. Powered by Small World Social
Samsung has partnered with U.S. pharma
company Biogen to form Samsung Bioepis to
develop and manufacture biosimilars. It has
also secured a marketing agreement with
another U.S. group, Merck.
4Biolink.us

5. Powered by Small World Social
According to the Financial Times article, South
Korea wants “a big share of the $110 billion of
value that Citigroup expects to flow from
[originator biologics] companies to biosimilars
over the next decade. Seoul has set a goal to
increase pharmaceutical exports to Won23tn
(USD$20.5 billion) by 2020 – up tenfold from
the 2012 figure – when it wants to have three
of the world’s top 50 pharma companies”.
5Biolink.us

6. Powered by Small World Social
Celltrion’s Remsima/Inflectra was the first copy
of Johnson & Johnson/Merck’s rheumatoid
arthritis drug Remicade, the world’s third best-
selling drug last year with sales of $10 billion.
Launched in Europe in February, this biosimilar
is now sold in 40 countries worldwide. And
Merck took a hit earlier in the year when Orion
Oyj, the company marketing Remsima in
Norway, cut the local price for the drug by 69
per cent, nabbing half the market in that
country.
6Biolink.us

7. Powered by Small World Social
By partnering with Samsung Bioepis, Merck
could make up for this, given Samsung Bioepis
is awaiting European regulatory approval for its
own Remicade copy, along with their copy of
another arthritis drug, Pfizer/Amgen’s Enbrel.
And with promising clinical trial data for the two
drugs presented at the European League
Against Rheumatism (EULAR) Annual
Congress in Rome in June, approvals may not
be far off.
7Biolink.us

8. Powered by Small World Social
By partnering with Samsung Bioepis, Merck
could make up for this, given Samsung Bioepis
is awaiting European regulatory approval for its
own Remicade copy, along with their copy of
another arthritis drug, Pfizer/Amgen’s Enbrel.
And with promising clinical trial data for the two
drugs presented at the European League
Against Rheumatism (EULAR) Annual
Congress in Rome in June, approvals may not
be far off.
8Biolink.us

9. Powered by Small World Social
An article in FiercePharmaAsia.com quoted
Samsung Bioepis as saying it could launch its
Enbrel biosimilar in South Korea late this year
and in Europe in early 2016.
Read More on BioLink:
https://biolink.smallworldsocial.com/portal#/?id
=557f01b6aae3895e3b5a910f
9Biolink.us

10. Powered by Small World Social
www.biolink.us
Visit:
https://www.smallworldsocial.com/biolink/
to get the latest in biosimilar news curated
from around the world
Want to read more about
biosimilars?